-
Top Narrow Based Indexes For May 18 (NGLPF, CREE, PSTI)
Wednesday, May 18, 2011 - 11:40am | 171By 11:38 am, the Dow Jones Industrial Average was up 21.45 points, or 0.17%, to 12,501.03, while the broader Standard & Poor's 500 index had gained 5.39 points, or 0.41%. The NASDAQ composite index rose 14.22 points, or 0.51%. Some of the narrow based indexes that are driving the markets are...
-
ZIOPHARM Oncology Announces Filing of Resale Registration Statement for Previous Private Placement
Wednesday, May 18, 2011 - 9:58am | 167ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that on May 18, 2011 it filed a resale registration statement on Form S-3 with the United States Securities and Exchange Commission. The registration statement registers for resale common shares issued or issuable to Intrexon Corporation in a...
-
Morning Market Losers (CWTR, CTRN, TA, CLDX)
Wednesday, May 18, 2011 - 9:53am | 113Coldwater Creek Inc (NASDAQ: CWTR) shares moved down 21.92% to $2.28 at 9:52 am. CWTR issued downbeat Q1 projections. Citi Trends Inc (NASDAQ: CTRN) fell 20.18% to $17.09. CTRN reported downbeat Q1 results. TravelCenters of America LLC (AMEX: TA) dipped 14.89% to $6.40. TA initiated a public...
-
Nanosphere Announces Positive New Data Presented at the Annual Meeting of the American Urological Association Demonstrates Clinical Use for Nanosphere's Ultra-Sensitive PSA Assay
Wednesday, May 18, 2011 - 9:38am | 127Positive clinical studies using Nanosphere Inc.'s (Nasdaq: NSPH) Verisens™ ultra-sensitive PSA assay were presented in moderated poster sessions at the annual meeting of the American Urological Association. The test differentiated men with recurrent cancer from men with no recurrence in a study of...
-
Celldex Says 10M Shares Priced At $3.15 Each
Wednesday, May 18, 2011 - 9:03am | 124Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price to the public of $3.15 per share for an aggregate offering of $31,500,000 of common stock. The proceeds to Celldex from this offering...
-
Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Two Upcoming Investor Conferences
Wednesday, May 18, 2011 - 9:00am | 23LINCOLNSHIRE, Ill. - May 18, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will be presenting at two upcoming investors conferences on May 24, 2011.
-
Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Two Upcoming Investor Conferences
Wednesday, May 18, 2011 - 9:00am | 23LINCOLNSHIRE, Ill. - May 18, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will be presenting at two upcoming investors conferences on May 24, 2011.
-
Benzinga's Top Pre-Market NASDAQ Losers (CWTR, SPLS, CLDX, ARMH)
Wednesday, May 18, 2011 - 8:21am | 127Coldwater Creek Inc (NASDAQ: CWTR) dipped 21.23% to $2.30 in the pre-market session. CWTR issued downbeat Q1 projections. Staples Inc (NASDAQ: SPLS) fell 12.47% to $17.20 in the pre-market session. SPLS reported downbeat first-quarter results and lowered its profit projections for the year....
-
Bank of America Merrill Lynch Reports on Amgen
Wednesday, May 18, 2011 - 8:09am | 193In a report released yesterday, Bank of America Merrill Lynch commented on Amgen (NASDAQ: AMGN). In the report, Bank of America Merrill Lynch was mixed in its outlook on the company. Bank of America Merrill Lynch writes, “Our price objective of $62 is supported by our sum-of-the-parts DCF: $15/sh...
-
LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.
Wednesday, May 18, 2011 - 8:06am | 102Laboratory Corporation of America® Holdings (NYSE: LH) today announced that LabCorp is extending until 6:00 p.m., New York City time, on June 1, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ: ORCH). On May 17,...
-
OXiGENE Announces Clinical Data From FACT and FALCON Studies to be Presented at ASCO
Wednesday, May 18, 2011 - 8:05am | 55OXiGENE (Nasdaq: OXGN) announced today that data from its clinical trials of ZYBRESTAT in combination with chemotherapy in patients with anaplastic thyroid cancer and non-small cell lung cancer will be presented at the upcoming American Society of Clinical Oncology annual meeting in Chicago,...
-
LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark
Wednesday, May 18, 2011 - 8:00am | 102Laboratory Corporation of America® Holdings (NYSE: LH) today announced that LabCorp is extending until 6:00 p.m., New York City time, on June 1, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ: ORCH). On May 17,...
-
Collins Stewart Reports on United Therapeutics
Wednesday, May 18, 2011 - 7:45am | 154In a report released today, Collins Stewart commented on United Therapeutics (NASDAQ: UTHR). In the report, Collins Stewart was positive in its assessment of the company. Collins Stewart writes, “Our physician feedback suggests that the introduction of smaller doses has dramatically improved...
-
Bank of America Raises PT On Amgen To $62
Wednesday, May 18, 2011 - 7:02am | 27Bank of America has raised the price target on Amgen (NASDAQ: AMGN) from $60 to $62 and maintains its Neutral rating.
-
GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term
Wednesday, May 18, 2011 - 6:29am | 1757Isis Pharmaceuticals Inc. (ISIS) ended the first quarter, with nearly $427 million in cash. Revenue for the three months ended March 31, 2011 was $21.1 million, compared to $29.9 million for the same period in 2010. Isis Pharmaceuticals earned a $3 million payment from GlaxoSmithKline (GSK) to...